Vantage logo

The cost to Astrazeneca of building Brilinta

Thales, the final Brilinta outcome trial in Astrazeneca’s huge Parthenon programme, has hit – but the UK group’s vast investment in its blood thinner has yet to pay off.

Vantage logo

Amarin enters the home stretch

After an overwhelmingly positive adcom, the outstanding question around Vascepa is just how big the product might become.